Tirzepatide 30 mg

Tirzepatide 30 mg (GIP/GLP-1 Receptor Agonist)

This long-acting peptide activates two incretin receptors: glucose-dependent insulinotropic polypeptide, known as GIP, and glucagon-like peptide-1, known as GLP-1. Tirzepatide Canada research therefore focuses on sustained dual-receptor signalling and metabolic regulation.

One major research area involves the relationship between incretin activity and insulin release. Scientists examine how GIP and GLP-1 pathways influence glucose-dependent insulin signalling, glucagon activity, and glucose regulation.

In addition, laboratory studies explore appetite and food-intake pathways. Brain regions involved in appetite regulation contain both receptor types. As a result, this dual mechanism provides a useful model for investigating energy intake and body-weight regulation.

Because tirzepatide has extended activity, researchers can study sustained incretin-receptor activation. Related work covers body composition, adipose tissue, lipid handling, insulin sensitivity, and broader cardiometabolic pathways.

For comparison, Semaglutide selectively activates the GLP-1 receptor. Researchers can also explore Retatrutide, a triple-receptor agonist studied for activity at GIP, GLP-1, and glucagon receptors. Alternatively, 5-Amino-1MQ offers a non-incretin model focused on NNMT inhibition. For a side-by-side overview, read our Semaglutide vs. Tirzepatide vs. Retatrutide comparison.

Overall, tirzepatide offers a dual-pathway model for studying incretin signalling, appetite, glucose metabolism, insulin activity, and body composition.

Product Specifications

• Form: Lyophilized powder
• Scientific / alternate name: LY3298176
• Vial size: 30 mg

For laboratory and research purposes only. Not intended for human or veterinary use, diagnosis, treatment, or consumption.